VJHemOnc is committed to improving our service to you

EHA 2015 | Immunomodulators, proteasome inhibitors and monoclonal antibodies for multiple myeloma

VJHemOnc is committed to improving our service to you

Pieter Sonneveld

There is currently no standard treatment for patients with relapsed or refractory multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses promising agents for this patient population, including immunomodulatory agents, such as lenalidomide and pomalidomide; proteasome inhibitors, such as carfilzomib; and monoclonal antibodies, such as daratumumab and elotuzumab.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter